National Brain Tumor Society launched our Defeat GBM Research Collaborative in March of 2013 to great enthusiasm from both the patient and scientific communities. As our boldest strategic research initiative to-date, the Defeat GBM Research Collaborative aims to double the five-year survival rate of glioblastoma multiforme (GBM) patients in just five years.
Dr. David Louis, Pathologist-in-Chief at Massachusetts General Hospital (MGH) and Benjamin Castleman Professor of Pathology at Harvard Medical School, is an internationally recognized expert in brain tumor pathology and molecular genetics.
National Brain Tumor Society hosted the inaugural Advancing Research to Therapies (ART) for Brain Tumors Conference in Washington, D.C. during Brain Tumor Awareness Month in May, 2013. The ART Conference brought together more than 100 leading experts from academic research labs, government agencies, biotech and pharmaceutical companies, and venture capital firms